Loading the company…
Loading the company…
Families: SI joint fusion, Bone graft & orthobiologics, Lumbar fusion.
All companies · Product and company coverage
In the last ten years FDA made 14 decisions for Surgentec (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 3 procedure families, the most in 2024 (5). The latest was on 2026-10-14.
| Family | Decisions on record |
|---|---|
| SI joint fusion | 8 |
| Bone graft & orthobiologics | 5 |
| Lumbar fusion | 5 |
In 2025, Surgentec reported engagement with 39 surgeons and other clinicians in the states MedaRep covers, worth $238K in consulting, speaking, meals and travel for its device products, the most in Florida ($68K to 7). Royalties are left out.
| TiLink-P SI Joint Fusion System |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Surgentec.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Florida ($68K, 7 engaged), Texas ($61K, 7 engaged), Oklahoma ($36K, 2 engaged), Indiana ($24K, 6 engaged), California ($13K, 2 engaged).